

# The Belgian decision on herpes zoster vaccination in adults in the national immunization program

Isabel Leroux-Roels, MD PhD

18 April 2024

Prague, European Adult Immunization Board

# The Belgian decision on herpes zoster vaccination in adults ~~in the national immunization program~~

Isabel Leroux-Roels, MD PhD

18 April 2024

Prague, European Adult Immunization Board

## Conflict of interest statement


ILR is the principal investigator of several clinical vaccine trials commissioned by pharmaceutical and biotech companies.

Her institutions (UZ Gent/UGent) are paid for these services. ILR does not receive any personal funding or payment from industry.

GSK provided assistance in providing information on some of the next slides. The content of these slides reflects my personal opinion.

ILR is a member of the vaccination working group of the Superior Health Council (Belgian NITAG)


# Timeline of the recombinant herpes zoster (RHZ) vaccine in Belgium



Vaccine is available + recommended + reimbursed (for selected patient groups)  
≠ immunization programme  
Vaccination coverage is still very low

\* Prior recommendations for the live HZ vaccine (2017)

# Vaccination policy in Belgium: federal versus regional level



## Federal level: Ministry of Health, Food Chain Safety and Environment

- RIZIV/INAMI: reimbursement of medical care, incl. medicines/vaccines
- Federal Agency for Medicines and Health Products (FAMHP): safety, quality, ...
- Superior Health Council (NITAG): vaccine recommendations
- Healthcare Knowledge Center (KCE): cost-effectiveness analyses

## Regional level (Flanders, French speaking community)

### → Flanders: Department of Care

- Preventive medicine, e.g. vaccination, well baby clinics, school medicine
- Immunization schedule and programmes, incl. tender purchases
- Flemish vaccination targets for 2030 (e.g. 80% flu and 50% PCV in 65+)


2% of Belgian health care budget is spent on preventive health care  
(WHO recommendation is 5%)

# BASISVACCINATIESCHEMA



Vlaanderen  
is zorgzaam en  
gezond samenleven

## Aanbevolen vaccinatiemomenten voor kinderen



# CALENDRIER DE VACCINATION

## 2023-2024

|  |            | Nourrissons        |                     |                     |         |                         | Enfants et adolescents |                         |              |                | Adultes             |                    |           |
|--|------------|--------------------|---------------------|---------------------|---------|-------------------------|------------------------|-------------------------|--------------|----------------|---------------------|--------------------|-----------|
|  |            | 8 sem.<br>(2 mois) | 12 sem.<br>(3 mois) | 16 sem.<br>(4 mois) | 12 mois | 15 <sup>①</sup><br>mois | 5-6<br>ans             | 7-8 <sup>②</sup><br>ans | 13-14<br>ans | 15-16<br>ans   | Femmes<br>enceintes | Tous les<br>10 ans | 65<br>ans |
| Poliomyélite                           | Hexavalent | ✓                  | ✓                   | ✓                   |         | ✓                       |                        |                         |              |                | ✓ <sup>⑤</sup>      | ✓                  |           |
| Diphtérie                              |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| Tétanos                                |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| Coqueluche                             |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| <i>Haemophilus influenza</i> de type b |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| Hépatite B                             |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| Rougeole                               | RRO        |                    |                     |                     | ✓       |                         |                        |                         |              |                |                     |                    |           |
| Rubéole                                |            |                    |                     |                     |         |                         | ✓                      |                         |              |                |                     |                    |           |
| Oreillons                              |            |                    |                     |                     |         |                         |                        |                         |              |                |                     |                    |           |
| Méningocoques ACWY                     |            |                    |                     |                     | ✓       |                         |                        |                         |              |                |                     |                    |           |
| Pneumocoques                           |            | ✓                  | (✓) <sup>①</sup>    | ✓ <sup>③</sup>      | ✓       |                         |                        |                         |              |                |                     | ✓                  |           |
| Rotavirus (vaccin oral)                |            | ✓                  | ✓                   | (✓) <sup>③</sup>    |         |                         |                        |                         |              |                |                     |                    |           |
| Papillomavirus (HPV)                   |            |                    |                     |                     |         |                         | ✓                      | ✓ <sup>④</sup>          |              |                |                     |                    |           |
| Grippe (Influenza)                     |            |                    |                     |                     |         |                         |                        |                         |              | ✓ <sup>⑥</sup> |                     | ✓                  |           |



Recommandé à tous et gratuit



Recommandé à tous



Vaccin combiné (une seule injection)



① Pour les bébés nés avant 37 semaines de grossesse, une dose supplémentaire de vaccin contre le pneumocoque est recommandée à 3 mois et les vaccins prévus à 15 mois seront administrés à 13 mois (hexavalent et méningocoques ACWY).

**Hexavalent** : Vaccin qui confère une protection contre 6 maladies



② Depuis septembre 2020, la deuxième dose du vaccin RRO est administrée à 7-8 ans. Les enfants plus âgés qui n'ont pas encore reçu la vaccination peuvent être vaccinés à 11-12 ans.



③ En 2 ou 3 doses en fonction du vaccin administré.



④ Vaccination en 2 doses à 6 mois d'intervalle (minimum 5 mois d'écart).



⑤ À partir de 24 semaines et idéalement avant 32 semaines de grossesse.



⑥ Pendant la saison grippale, quel que soit le stade de la grossesse.

**Ce calendrier est susceptible d'être modifié au fil des ans.**

Votre médecin pourra éventuellement l'adapter à votre enfant, n'hésitez pas à discuter vaccination avec lui.

**Pour plus d'infos :**

Consultez votre médecin traitant ou le site

[www.vaccination-info.be](http://www.vaccination-info.be)



# From vaccine recommendation to implementation

National recommendations  
(NITAG)



Based on recommendations,  
budget, feasibility, ...

Added to the vaccination  
programme



Not added to the  
vaccination programme



- Vaccines are purchased by the regional governments
- Provided for free to vaccinators (GPs, pediatricians, well baby clinics, school medicine), registration in Vaccinnet
- It concerns
  - Basic vaccines for children and adolescents
  - Booster dose for DTP for all adults
  - Influenza vaccines for nursing home residents

Request for federal reimbursement (RIZIV/INAMI)  
for patient categories (e.g. age, risk factors)

Accepted

Partially/Not accepted




# Belgian NITAG recommendations for HZ vaccination

The SHC recommends vaccination against herpes zoster (shingles) using a recombinant, non-live adjuvanted subunit herpes zoster vaccine (2-dose schedule) for



**Immunocompetent adults aged  
≥ 60 years**



**Immunocompromised patients, including  
those on immunosuppressive therapy aged  
≥ 16 years and also patients on  
JAK inhibitors**

The SHC is aware of the high costs currently associated with this vaccine (€162,85 per dose in April 2024) and proposes to take into account cost-effectiveness analyses and the results of the ongoing evaluation of the health technology of the Shingrix vaccine by the KCE (expected soon).



# KCE evaluation of cost-effectiveness of Shingrix

## Not cost-effective at current pricing


### -ICER (incremental cost-effectiveness ratios)

- between € 60 000 and 146 000
- max. threshold € 20 000 – 40 000 per QALY gained
- to be cost-effective: vaccine price decrease to € 30-50
- duration of protection and incidence key input parameters

Pieters *et al.*/KCE do not take into account the **higher incidence in immunocompromised** people and therefore **underestimate the real incidence of HZ, and consequently that of PHN.**

**Post-herpetic neuralgia (PHN)** incidence data were collected from immunocompetent individuals, while **PHN incidence increases with age but also in case of immune deficiency.**

**The exclusion of immunocompromised does not allow to show the value of Shingrix** which is indicated in immunocompromised populations




# Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

Nikolaos Giannelos, Cheryl Ng & Desmond Curran

- Out of **18 selected studies**, RZV vaccination against herpes zoster and post-herpetic neuralgia is **cost-effective in 15**.
- In the 15 studies establishing RZV cost-effectiveness, RZV is **always cost-effective** or **frequently cost-saving** in direct comparisons to ZVL, when applicable.
- RZV was found **cost-saving in several immune-compromised populations**.
- **Belgian CEA** has an atypically low CEA outcome → adjustments for incidence calculation (cfr previous slide)
- **Limitations of modeling studies**, e.g.
  - Input data are rapidly outdated
  - Should be updated when new evidence becomes available (e.g. longer follow up studies)
  - Some vaccination-related costs are not included (training, communication, logistics)
  - No differential utility losses for vaccinated and unvaccinated individuals

# Reimbursement procedure in Belgium


Classical procedure for new reimbursement requests\* (eg. Class 1, Class 2B)



(\*) Other procedures exist depending on the type of request

MEA: Managed Entry Agreement

# Various parameters are influencing the chances of success of a reimbursement request



**APPROVED**

Budget impact €


€€€€€

**NOT APPROVED**

**Immunocompromised patients**

- Patients most at risk of serious complications have easier access to RZV via lower co-payment

Population      Therapeutic value      EU prices  
 Recommendations      Adult Vx ecosystem      EE support  
 Medical need      ICER      Patient co-pay  
 Price      Budget



**Older adults**

- Proposal gives the opportunity to 65-80 yo to have easier access to RZV in a 5-year window

# Reimbursement of the recombinant HZ vaccine

Eligible for reimbursement as of 1st November 2023

The beneficiary is **at least 18 years old** and **meets at least one of the following conditions:**



Has a **hematological malignancy** or **other malignant tumor** and has undergone **active treatment** within the **last 5 years** prior to the **first administration** of this vaccine




Has been **infected** with **the human immunodeficiency virus (HIV)**




Has undergone or is eligible for a **hematopoietic stem cell transplantation** or **organ transplantation**

**No reimbursement for patients treated with JAK inhibitors and for haematology patients without active treatment**

# Conclusions



The recombinant zoster vaccine is available in Belgium since November 2020



NITAG recommendations are broad (all 60+ and immunocompromised 16+)




Cost-effectiveness analysis generated an atypically negative result compared to other CEA



No immunization programme for (older) adults at regional level





Reimbursement is approved since November 2023 for (selected) groups of immunocompromised patients



Vaccination coverage in at risk groups is increasing, but still very low (exact %?)

COPD = chronic obstructive pulmonary disease  
RA = rheumatoid arthritis  
HSCT = hematopoietic stem cell transplantation  
IBD = inflammatory bowel disease  
JAK-I = Janus kinase inhibitors therapy  
SOT = solid organ transplantation  
DM = diabetes mellitus  
CVD = cardiovascular disease  
IS = immunosuppressive therapy  
SLE = systemic lupus erythematosus

- Countries with both RZV/ZVL recommendations
- Countries with exclusive ZVL recommendations
- Countries with exclusive RZV recommendations
- Funded



**Belgium**

60+ gen. pop. (RZV)

\* F 16+ IS therapy

(\*funding in 18+, onco/hem, HIV, SOT, SCT)

**Norway**

50+ gen. pop. (RZV/ZVL)

18+ at increased HZ risk (immunosupp./severe disease) (RZV)

**Sweden**

50+ gen. pop. (RZV/ZVL)

18+ at increas. HZ risk (not specified) (RZV)

**The Netherlands**

60+ gen. pop. (RZV)

F 18+ immunoc. (HSCT, solid tumors, hemat. malign., SOT, HIV) (RZV)

**Germany**

F 60+ gen. pop. (RZV)

F 50+ at increas. HZ risk (immunosuppress./severe disease) (RZV)

**Poland**

\* F 50+ gen. pop. (RZV)

18+ at increased HZ risk (immunosup./comorbidities) (RZV)

(\*50% funded in 65+ with comorbidities)

**Ireland**

50+ gen. population (RZV/ZVL)

18+ at increased risk (RZV)

**Luxembourg**

F 65+ gen. pop. (RZV)

F 18+ ID due to illness or therapy (RZV)

**Switzerland**

F 65+ gen. pop. (RZV)

F 50+ mod. risk (RZV)

F 18+ gen. risk (RZV)

65-79 gen. pop. (ZVL)

**Austria**

50+ gen. pop. (RZV)

18+ at increased HZ risk (immunosuppression/severe disease) (RZV)

**Czechia**

50+ gen. pop. (RZV)

18+ at increas. HZ risk (ID, SOT, HIV, SLE/psoriasis, RA, COPD, bronch, asthma, IBD, CKD, CVD, DM, hem./oncol. diseases) (RZV)

**Cyprus**

F 60+ gen. pop. (RZV)

F 18+ at increased risk (incl. severely immunosup./rheumatic pts under biological agents) (RZV)

**Spain**

F 65&80 gen. pop. & catch up (RZV)

F 50+ immunosup./immuno-modulatory tx (RZV)

F 18+ immunocompr. (HSCT, SOT, JAK-I, HIV, hemat. malign., solid tumors, 2+ HZ epis.) (RZV)

(funded at national level via regional tenders - implementation in progress until 2024)

**France**

65+ gen. pop. (RZV)

18+ immunocompr. (RZV)

**Italy**

\* F 65 gen. pop. (RZV/ZVL)

\* F 50+ at increased HZ risk (DM, CVD, COPD, bron. asthma) (RZV/ZVL)

\* F 18+ at increased HZ risk (ID, CKD/dialysis, recurr./serious HZ forms) (RZV)

(funded via regional tenders)  
\*not yet implemented in all regions

**Slovenia**

F 60+ gen. pop. (RZV/ZVL)

F 18+ IC most vulner. (RZV)

**Greece**

F 60+ general pop. (RZV)

F 18+ immunosupp. (RZV)

F 60-75 gen. pop. (ZVL)

**Israel**

F 65+ gen. pop. (RZV)

F 18+ at increased risk (HIV, HSCT, SOT, hemat. malignancies, solid tumors, SLE, severe COPD, severe CKD) (RZV)

Funding for SLE, COPD and CKD tbc



Isabel Leroux-Roels, MD PhD  
Medical microbiologist  
Head of the Center for Vaccinology (CEVAC)  
Ghent University and Ghent University Hospital


---

Universitair Ziekenhuis Gent  
C. Heymanslaan 10 | B 9000 Gent | Ingang 99 | route 995  
T +32 (0)9 332 20 68 | E [cevac@uzgent.be](mailto:cevac@uzgent.be)

[www.uzgent.be/cevac](http://www.uzgent.be/cevac)

Volg ons op 



 Countries with RZV funding

CLD = chronic lung disease  
 COPD = chronic obstructive pulmonary disease  
 RA = rheumatoid arthritis  
 HSCT = hematopoietic stem cell transplantation  
 JAK-I = Janus kinase inhibitors therapy  
 SOT = solid organ transplantation  
 DM = diabetes mellitus  
 CVD = cardiovascular disease  
 IS = immunosuppressive therapy  
 SLE = systemic lupus erythematosus  
 CKD = chronic kidney disease  
 AID = autoinflammatory diseases



**United Kingdom**

65&70\* gen. pop  
 50+\* at increased HZ risk (immunosuppression)  
 18+ SCT  
 (\*first step of implementation)

**Belgium**

18+ IS therapy (onco/hem. malign., HIV, SOT, SCT)

**The Netherlands**

18+ immunocompr. (HSCT, solid tumors, hemat. malign., SOT, HIV)

**Poland**

65+ with comorbidities (CVD, CLD, diabetes, CKD, ID, cancer, HIV, SOT, AID)  
 (50% funded)

**Germany**

60+ gen. pop.  
 50+ at increased HZ risk (immunosuppression/severe disease)

**Cyprus**

60+ gen. pop. (RZV)  
 18+ at increased risk (incl. severely immunosup. /rheumatic pts under biological agents) (RZV)

**Switzerland**

65+ gen. pop.  
 50+ mod. risk (eg. COPD, RA)  
 18+ high risk (eg. HSCT, JAK-I)

**Luxembourg**

65+ gen. pop.  
 18+ ID due to illness or tx

**Spain**

65&80 gen. pop. & catch up  
 50+ immunosup./immunomodulatory tx  
 18+ immunocompr. (HSCT, SOT, JAK-I, HIV, hemat. malign., solid tumors, 2+ HZ epis.)

**Italy**

65 general population  
 50+ at increased HZ risk (DM, CVD, COPD, bron. asthma)  
 18+ at increased HZ risk (ID, CKD/dialysis, recurr./serious HZ forms)

**Slovenia**

18+ IC most vulnerab.

**Greece**

60+ general pop.  
 18+ immunosupp.

**Israel**

65+ gen. pop.  
 18+ at increased risk (HIV, HSCT, SOT, hemat. malignancies, solid tumors, SLE, severe COPD, severe CKD)  
 Funding for SLE, COPD and CKD tbc

Only reactive use

(funded at national level via regional tenders - implementation in progress until 2024)

(funded via regional tenders)  
 \*not yet implemented in all regions

# SUPPLEMENTARY SLIDE

## Recommendations

| Country         | Link   | Last accessed     |
|-----------------|--|-------------------|
| Austria         | <a href="https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan-%C3%96sterreich.html">https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan-%C3%96sterreich.html</a><br><a href="https://www.sozialministerium.at/dam/jcr:eb64732e-1747-400a-beeb-6d069f781182/Impfplan_%C3%96sterreich_2023_Version_1.1.pdf">https://www.sozialministerium.at/dam/jcr:eb64732e-1747-400a-beeb-6d069f781182/Impfplan_%C3%96sterreich_2023_Version_1.1.pdf</a>   | 04 September 2023 |
| Belgium         | <a href="https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/9209_shc_advice_9209_zonaa5_pdt.pdf">https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/9209_shc_advice_9209_zonaa5_pdt.pdf</a>  | 04 September 2023 |
| Cyprus          | <a href="https://www.moh.gov.cy/moh/moh.nsf/All/424911081AD158A9C2258A36003EC664?OpenDocument">https://www.moh.gov.cy/moh/moh.nsf/All/424911081AD158A9C2258A36003EC664?OpenDocument</a>  | 29 February 2024  |
| Czechia         | <a href="https://www.nzip.cz/clanek/217-ockovaci-kalendar-pro-dospele">https://www.nzip.cz/clanek/217-ockovaci-kalendar-pro-dospele</a>  | 04 September 2023 |
| France          | <a href="https://www.has-sante.fr/jcms/p_3498915/fr/recommandations-vaccinales-contre-le-zona-place-du-vaccin-shingrix#:~:text=La%20HAS%20recommande%20la%20vaccination,avant%20l'initiation%20du%20traitement">https://www.has-sante.fr/jcms/p_3498915/fr/recommandations-vaccinales-contre-le-zona-place-du-vaccin-shingrix#:~:text=La%20HAS%20recommande%20la%20vaccination,avant%20l'initiation%20du%20traitement</a>  | 11 March 2024     |
| Germany         | <a href="https://www.rki.de/DE/Content/Infekt/Impfen/Materialien/Downloads-Impfkalender/Impfkalender_Englisch.pdf?__blob=publicationFile">https://www.rki.de/DE/Content/Infekt/Impfen/Materialien/Downloads-Impfkalender/Impfkalender_Englisch.pdf?__blob=publicationFile</a>  | 04 September 2023 |
| Greece          | <a href="http://diavgeia.gov.gr/decision/view/ΨΜ16465ΦΥ0-0ΦΚ">http://diavgeia.gov.gr/decision/view/ΨΜ16465ΦΥ0-0ΦΚ</a>  | 11 March 2024     |
| Ireland         | <a href="https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter23.pdf">https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter23.pdf</a>  | 04 September 2023 |
| Israel          | משרד הבריאות – אגף לאפידמיולוגיה, תדריך חיסונים, מאי 2023 - תרכיב רקומביננטי נגד שלבכת חוגרת<br>משרד הבריאות -יח' באייר תשפ"ג - 9/5/2023 - סימוכין: 13934703217  | 04 September 2023 |
| Italy           | <a href="https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&amp;page=newsett">https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&amp;page=newsett</a>  | 04 September 2023 |
| Luxembourg      | <a href="https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/zona/csmi-recommandation-vaccination-zona-vf.pdf">https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/zona/csmi-recommandation-vaccination-zona-vf.pdf</a>  | 04 September 2023 |
| The Netherlands | <a href="https://www.gezondheidsraad.nl/binaries/gezondheidsraad/documenten/adviezen/2019/07/15/vaccinatie-tegen-gordelroos/advies+Vaccinatie+tegen+gordelroos.pdf">https://www.gezondheidsraad.nl/binaries/gezondheidsraad/documenten/adviezen/2019/07/15/vaccinatie-tegen-gordelroos/advies+Vaccinatie+tegen+gordelroos.pdf</a>  | 04 September 2023 |
| Norway          | <a href="https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/varicella--og-herpes-zostervaksinas/#vaksiner-mot-varicella-og-herpes-zoster">https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/varicella--og-herpes-zostervaksinas/#vaksiner-mot-varicella-og-herpes-zoster</a>  | 04 September 2023 |
| Poland          | Medycyna Praktyczna, 5 (387) maj 2023  | 04 September 2023 |
| Slovenia        | <a href="https://nizj.si/wp-content/uploads/2023/10/Priporocila-HZ_27okt2023.pdf">https://nizj.si/wp-content/uploads/2023/10/Priporocila-HZ_27okt2023.pdf</a><br><a href="https://nizj.si/wp-content/uploads/2023/09/Navodila-za-izvajanje-IP-2023.pdf">https://nizj.si/wp-content/uploads/2023/09/Navodila-za-izvajanje-IP-2023.pdf</a>   | 29 February 2024  |
| Spain           | <a href="https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf">https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf</a><br><a href="https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf">https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf</a> | 04 September 2023 |
| Sweden          | <a href="https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/vacciner-a-o/baltros/">https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/vacciner-a-o/baltros/</a>  | 04 September 2023 |
| Switzerland     | <a href="https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/windpocken.html">https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/windpocken.html</a> (DE)<br><a href="https://www.bag.admin.ch/bag/fr/home/krankheiten/krankheiten-im-ueberblick/windpocken.html">https://www.bag.admin.ch/bag/fr/home/krankheiten/krankheiten-im-ueberblick/windpocken.html</a> (FR)<br><a href="https://www.bag.admin.ch/bag/it/home/krankheiten/krankheiten-im-ueberblick/windpocken.html">https://www.bag.admin.ch/bag/it/home/krankheiten/krankheiten-im-ueberblick/windpocken.html</a> (IT)                 | 04 September 2023 |
| United Kingdom  | <a href="https://www.england.nhs.uk/long-read/changes-to-the-gp-contract-in-2023-24/#annex-a-changes-to-the-gp-contract-in-2023-24">https://www.england.nhs.uk/long-read/changes-to-the-gp-contract-in-2023-24/#annex-a-changes-to-the-gp-contract-in-2023-24</a><br><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1174008/Shingles_Green_Book_on_Immunisation_Chapter_28a_26_7_23.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1174008/Shingles_Green_Book_on_Immunisation_Chapter_28a_26_7_23.pdf</a>                       | 04 September 2023 |

# SUPPLEMENTARY SLIDE

## Funding

| Country         | Link   | Last accessed     |
|-----------------|--|-------------------|
| Cyprus          | <a href="https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=46&amp;IncludeChildAgeGroup=true&amp;IncludeChildAgeGroup=false&amp;IncludeAdultAgeGroup=true&amp;IncludeAdultAgeGroup=false">https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=46&amp;IncludeChildAgeGroup=true&amp;IncludeChildAgeGroup=false&amp;IncludeAdultAgeGroup=true&amp;IncludeAdultAgeGroup=false</a>  | 29 February 2024  |
| France          | <a href="https://www.mesvaccins.net/textes/CT-13478_ZOSTAVAX_PIC_Ins_Avis3_CT13478.pdf">https://www.mesvaccins.net/textes/CT-13478_ZOSTAVAX_PIC_Ins_Avis3_CT13478.pdf</a>  | 04 September 2023 |
| Germany         | <a href="https://www.g-ba.de/downloads/17-98-5009/2020-07-23_G-BA_Geschaeftsbericht_2019_bf.pdf">https://www.g-ba.de/downloads/17-98-5009/2020-07-23_G-BA_Geschaeftsbericht_2019_bf.pdf</a>  | 04 September 2023 |
| Greece          | <a href="http://diavgeia.gov.gr/decision/view/ΨΜ16465ΦΥ0-0ΦΚ">http://diavgeia.gov.gr/decision/view/ΨΜ16465ΦΥ0-0ΦΚ</a>  | 11 March 2024     |
| Italy           | <a href="https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&amp;page=newsett">https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&amp;page=newsett</a>  | 04 September 2023 |
| Israel          | משרד הבריאות יח' באייר תשפ"ג - 9/5/2023 - סימוכין: 13934703217   | 04 September 2023 |
| Luxembourg      | <a href="https://gouvernement.lu/fr/actualites/toutes_actualites/communiqués/2023/04-avril/12-vaccin-gratuit-zona.html">https://gouvernement.lu/fr/actualites/toutes_actualites/communiqués/2023/04-avril/12-vaccin-gratuit-zona.html</a>  | 04 September 2023 |
| The Netherlands | <a href="https://zoek.officielebekendmakingen.nl/stcrt-2021-37096.html">https://zoek.officielebekendmakingen.nl/stcrt-2021-37096.html</a><br><a href="https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/06/14/gvs-advies-shingrix">https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/06/14/gvs-advies-shingrix</a>   | 04 September 2023 |
| Portugal        | <a href="https://extranet.infarmed.pt/INFOMED-fo/index.xhtml">https://extranet.infarmed.pt/INFOMED-fo/index.xhtml</a>  | 04 September 2023 |
| Slovenia        | <a href="https://niz.si/wp-content/uploads/2023/10/Priporocila-HZ_27okt2023.pdf">https://niz.si/wp-content/uploads/2023/10/Priporocila-HZ_27okt2023.pdf</a><br><a href="https://niz.si/wp-content/uploads/2023/09/Navodila-za-izvajanje-IP-2023.pdf">https://niz.si/wp-content/uploads/2023/09/Navodila-za-izvajanje-IP-2023.pdf</a>   | 29 February 2024  |
| Spain           | <a href="https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf">https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf</a>  | 04 September 2023 |
| Switzerland     | <a href="https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/i-und-b/richtlinien-empfehlungen/neue-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf">https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/i-und-b/richtlinien-empfehlungen/neue-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf</a><br><a href="https://www.admin.ch/gov/fr/accueil/documentation/communiqués.msg-id-86279.html">https://www.admin.ch/gov/fr/accueil/documentation/communiqués.msg-id-86279.html</a> | 04 September 2023 |
| United Kingdom  | <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1174008/Shingles_Green_Book_on_Immunisation_Chapter_28a_26_7_23.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1174008/Shingles_Green_Book_on_Immunisation_Chapter_28a_26_7_23.pdf</a>  | 04 September 2023 |

For Belgium: Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products via [adr@afmps.be](mailto:adr@afmps.be) or via [www.notifierunefetindesirable.be](http://www.notifierunefetindesirable.be) or to GlaxoSmithKline Pharmaceuticals s.a./n.v. via [be.medinfo@gsk.com](mailto:be.medinfo@gsk.com).

For Luxembourg: Please report adverse events to the Centre Régional de Pharmacovigilance de Nancy or Division de la pharmacie et des médicaments de la Direction de la santé via [www.guichet.lu/pharmacovigilance](http://www.guichet.lu/pharmacovigilance) or to GlaxoSmithKline Pharmaceuticals s.a./n.v. via [be.medinfo@gsk.com](mailto:be.medinfo@gsk.com).

SmPC RZV NL: <https://www.e-compendium.be/nl/bijsluiters/wetenschappelijk/7514/18320> - SmPC RZV FR: <https://www.e-compendium.be/fr/notices/scientifique/7514/18320>

NP-BE-SGX-PPT-240006 – April 2024

© 2024 GlaxoSmithKline Pharmaceuticals s.a./n.v. Site Avenue Fleming 20, 1300 Wavre Belgium